Please assess the completion status of the following clinical trial:

Trial Title: Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with penicillin allergy who have non-ulcer functional dyspepsia or scarred peptic ulcer disease~* Ability and willingness to participate in the study and to sign and give informed consent~* confirmed H. pylori infection~Exclusion Criteria:~* Patients without penicillin allergy~* Less than 18 years old~* With previous gastric surgery~* Major systemic diseases~* Pregnancy or lactation~* Allergy to any of the study drugs~* Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tailored Therapy (Type: EXPERIMENTAL): Medications will be adjusted according to clarithromycin，metronidazole and levofloxacin sensitivity. All drugs will be prescribed for 14 days.(1) When three of them or clarithromycin and metronidazole are sensitive, esomeprazole 20mg bid, clarithromycin 0.5g bid and metronidazole 0.4g bid will be prescribed. (2) When two of them (levofloxacin and clarithromycin or metronidazole) are sensitive, esomeprazole 20mg bid, levofloxacin 0.5g qd plus clarithromycin 0.5g bid or metronidazole 0.4g bid will be prescribed. (3) When one of them (clarithromycin or levofloxacin) is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus clarithromycin 0.5g bid or levofloxacin 0.5g qd will be prescribed.(4) When only metronidazole or none of them is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus tetracycline 0.4g qid will be prescribed.

Based on this trial design, predict the completion outcome and termination type (if applicable).